Evolving targets for heart failure: the journey so far

Published: November 28, 2023
Abstract Views: 1346
pdf: 52
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


The treatment of heart failure has included vasodilators, positive inotropes and most successfully neurohormonal blockade. Recent research has looked at metabolic and immune modulatory approaches, and implantable, mainly electrical devices. The near future in pharmacological research for heart failure remains focused on classic methodologies and small molecules, but despite significant improvements we still know relatively little of the complex interactions in heart failure, particularly for heart failure with preserved ejection fraction. Pharmacotherapy will in future be combined with advances in biotechnology, nanotechnology and devices and a digital revolution will help us to monitor patients at a distance, using wireless devices. Heart failure research has achieved much over the last 4 decades, but the pace of innovation and research has not abated and future advances in this disabling condition are indeed likely.



PlumX Metrics


Download data is not yet available.


How to Cite

Rosano, G. M., & Farkas, J. (2023). Evolving targets for heart failure: the journey so far. Global Cardiology, 1(1). https://doi.org/10.4081/cardio.2023.6

Similar Articles

You may also start an advanced similarity search for this article.